Havrix

Havrix is an injectable hepatitis A vaccine containing inactivated hepatitis A virus and algeldrate as an adjuvant. It is supplied as a sterile solution for intramuscular administration and is marketed in the European Union as a prescription product. The vaccine works by stimulating the immune system to produce protective antibodies against hepatitis A virus, providing active immunity for individuals at risk of infection in adults and children.

Havrix is indicated for the prevention of hepatitis A infection in people who are at increased risk of exposure or who seek immunity through vaccination.

- Travel to regions where hepatitis A is endemic or where outbreaks have been reported. - Occupational exposure for healthcare workers, laboratory personnel, or others handling infectious material. - Household contacts of individuals diagnosed with hepatitis A. - Individuals with chronic liver disease or clotting-factor disorders. - Men who have sex with men and other high‑risk groups. - Pre‑exposure prophylaxis for travelers and military personnel.

The safety profile of Havrix reflects the typical reactions observed with inactivated vaccines, most of which are mild and transient.

Common: - Pain, redness, or swelling at the injection site. - Mild fever or chills. - Headache or fatigue. - Muscle aches or joint discomfort. - Nausea or mild gastrointestinal upset. - Mild rash at or near the injection site.

Serious: - Allergic reactions such as hives, swelling of the face, or difficulty breathing. - Neurological events including Guillain‑Barré syndrome (very rare). - Severe fever or persistent vomiting. - Unexplained fainting or loss of consciousness.

Before receiving Havrix, certain health considerations should be reviewed to ensure the vaccine is appropriate and safe for the individual.

- Known severe allergy to any component of the vaccine, including algeldrate. - History of a severe allergic reaction to a previous dose of Havrix. - Acute moderate or severe illness at the time of vaccination. - Pregnancy status should be discussed with a healthcare professional. - Immunocompromised individuals may have a reduced antibody response. - Children under the age approved by local regulations should follow specific dosing guidelines. - Individuals with bleeding disorders should be observed after intramuscular injection.

Havrix does not have many documented drug interactions, but certain substances or conditions may affect its administration or immune response.

Avoid: - Concurrent administration of other live vaccines at the same anatomical site. - Use of immunosuppressive therapy that may diminish vaccine efficacy.

Use with caution: - Concurrent use of antipyretics or analgesics may mask mild post‑vaccination symptoms. - Patients receiving blood products or immunoglobulins should wait at least 4 weeks after vaccination. - Individuals on chronic corticosteroid therapy may have a reduced immune response. - Pregnant or lactating women should discuss timing of vaccination with their provider.